WEBULL
News
IPHA
1.893
-0.37%
-0.007
Weekly Report: what happened at IPHA last week (1201-1205)?
Weekly Report · 1d ago
Weekly Report: what happened at IPHA last week (1124-1128)?
Weekly Report · 12/01 09:10
Innate Pharma Reports Updated Share and Voting Rights Totals
Reuters · 11/28 06:00
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025
Barchart · 11/28 00:00
Weekly Report: what happened at IPHA last week (1117-1121)?
Weekly Report · 11/24 09:10
Weekly Report: what happened at IPHA last week (1110-1114)?
Weekly Report · 11/17 09:10
Innate Pharma SA to Present at Jefferies Global Healthcare Conference
Reuters · 11/17 06:00
Innate Pharma reports 9M results
Seeking Alpha · 11/13 11:32
Innate Pharma Reports €56.4M Cash And €2.3M Nine-Month Revenue As Lacutamab Advances Toward TELLOMAK-3 Phase 3 Initiation In 2026
Benzinga · 11/13 06:18
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
Reuters · 11/13 06:08
Innate Pharma reports €2.3 million revenue for first nine months of 2025
Reuters · 11/13 06:00
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 11/11 12:07
Why Rocket Lab Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Benzinga · 11/11 10:55
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 11/10 17:07
Pre-Market Most Active for Nov 10, 2025 : IFRX, GREE, IPHA, TSLL, SQQQ, NVDA, PFE, BBAI, OSCR, IONQ, HLN, THS
NASDAQ · 11/10 13:28
Innate Pharma announces FDA clearance to proceed with TELLOMAK 3 trial
TipRanks · 11/10 11:00
Weekly Report: what happened at IPHA last week (1103-1107)?
Weekly Report · 11/10 09:10
Innate Pharma Gains FDA Clearance To Launch TELLOMAK 3 Phase 3 Trial Of Lacutamab In Sézary Syndrome And Mycosis Fungoides
Benzinga · 11/10 06:32
FDA Clears Innate Pharma to Begin Phase 3 Trial of Lacutamab in CTCL
Reuters · 11/10 06:00
Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
Barchart · 11/10 00:00
More
Webull provides a variety of real-time IPHA stock news. You can receive the latest news about Innate Pharma Sa through multiple platforms. This information may help you make smarter investment decisions.
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.